26th week of 2013 patent applcation highlights part 42 |
Patent application number | Title | Published |
20130164277 | Compositions and methods including B lymphocyte cell line expressing membrane immunoglobulin different from secreted immunoglobulin - Compositions and methods are disclosed herein for producing one or more immunoglobulins in an isolated B lymphocyte cell line. An isolated recombinant cell line includes an isolated B lymphocyte cell line capable of expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and at least one exogenously incorporated nucleic acid encoding at least one secreted immunoglobulin reactive to a second antigen. | 2013-06-27 |
20130164278 | HUMANIZED ANTIBODY - The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. | 2013-06-27 |
20130164279 | Micro RNA-148A as a Biomarker for Advanced Colorectal Cancer - The present invention includes methods of detection, diagnosis, prognosis, and treatment of a patient suspected of having a colorectal cancer comprising obtaining one or more samples of the patient, determining a level of expression of miR-148a or the level of methylation of a miR-148a promoter, and predicting a response to a cytotoxic chemotherapy cancer treatment. | 2013-06-27 |
20130164280 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS - The invention provides compounds and pharmaceutically acceptable salts and esters and compositions thereof, for treating viral infections. The compounds and compositions are useful for treating Pneumovirinae virus infection including Human respiratory syncytial virus infections. | 2013-06-27 |
20130164281 | DEIMMUNIZED ANTI C-MET HUMANIZED ANTIBODIES AND USES THEREOF - A deimmunized anti c-Met humanized antibody and a pharmaceutical composition including the same, and method for the prevention and treatment of cancer. | 2013-06-27 |
20130164282 | TREATMENT OF CANCER - Provided are methods relating to compositions that include a CDP-topoisomerase inhibitor, e.g., a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101. | 2013-06-27 |
20130164283 | Antibody induced cell membrane wounding - Compositions and methods for inducing cell membrane wounding, cell permeabilization and cell killing are provided. The composition comprises a polyvalent agent that binds to a highly expressed cell surface antigen present on the surface of a cell. Preferably, the cell surface antigen is associated with the cytoskeleton of the cell. A preferred polyvalent agent is an IgM, and enhanced cell wounding and killing can be provided by the addition of a crosslinking agent. At sublethal concentrations in vivo, the cell wounding antibodies permeabilize cells and dramatically enhance response to chemotherapeutic agents, even in patients refractory to the chemotherapeutic agents. | 2013-06-27 |
20130164284 | COMPOSITIONS AND METHODS TO TREAT BONE RELATED DISORDERS - The present invention relates to the use of modulators of the sclerostin: sclerostin-binding-partner interaction for the treatment, amelioration, and diagnosis of sclerostin-related disorders, e.g., osteoporosis and sclerosteosis, and sclerostin-related disorders, e.g., cancers and cardiovascular disorders. The invention also relates to the use of sclerostin-binding-partner mimetics for the treatment, amelioration, and diagnosis of sclerostin-related disorders. Assays for the identification of modulators of the sclerostin: sclerostin-binding-partner interaction, as well as the resulting signaling, are also provided. | 2013-06-27 |
20130164285 | Water-in-Oil Type Emulsion for Treating a Disease of the Eye - The invention relates to a composition for administering with a sustained release kinetic a therapeutically effective amount of a therapeutic agent to a subject in need thereof for treating diseases or conditions of the eye, wherein the composition is an water-in-oil type emulsion comprising an oil phase, a lipophilic surfactant dissolved in the oil phase, an aqueous phase dispersed in the oil phase, a hydrophilic therapeutic agent dissolved in the aqueous dispersed phase, and wherein the composition is intraocularly injectable, wherein the composition has a density lower than 1. The invention also relates to a pharmaceutical composition or to a medicament comprising the composition of the invention, and to a method for treating a condition or disease of the eye comprising administering a therapeutic amount of the composition of the invention. The invention also relates to a device comprising the composition of the invention. | 2013-06-27 |
20130164286 | Fc FUSION PROTEINS - The embodiments of the invention relate to compositions, methods, and kits comprising a fusion protein. The fusion proteins of the embodiments include monomer polypeptides which in one embodiment have at least a binding domain, an optional hinge region, a collagen-like domain and the Fc domain of a human IgG. | 2013-06-27 |
20130164287 | SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR TREATMENT OF MEDICAL DISORDERS - The invention pertains to methods and compositions for treating medical disorders characterized by elevated levels or abnormal expression of TNFα by administering a TNFα antagonist, such as recombinant TNFR:Fc. | 2013-06-27 |
20130164288 | READTHROUGH ACETYLCHOLINESTERASE (ACHE-R) FOR TREATING OR PREVENTING PARKINSON'S DISEASE - A method of treating or preventing Parkinson's disease in a subject in need thereof is disclosed. The method comprises administering to the subject a therapeutically effective amount of AChE-R, wherein the AChE-R is devoid of an N-terminal extension. An additional method of treating or preventing Parkinson's disease in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of AChE-R, wherein the AChE-R comprises a modification for increasing bioavailability. | 2013-06-27 |
20130164289 | HUMAN CYTOMEGALOVIRUS VACCINE - Combination peptides, polypeptides and proteins that elicit high titer neutralizing antibodies against cytomegalovirus (CMV) are provided. The combination peptides, polypeptides and proteins encompass epitopes located within the UL130 and UL131 components of the gH/gL/UL128-131 protein complex, in particular, epitopes located within amino acid residues 27-46 of UL130 and amino acid residues 90-106 of UL131. The combination peptides, polypeptides and proteins, and the nucleic acids encoding them, may be used in vaccines, and as diagnostic and research tools. | 2013-06-27 |
20130164290 | Artificially Produced Polyclonal Immunoglobulin Preparation - The present invention intended to provide an artificial polyclonal immunoglobulin composition having a high therapeutic effect and high safety, and being capable of stable supply in a large amount. Specifically provided is an artificial polyclonal immunoglobulin composition containing, as active ingredients, 204 polypeptides represented by amino acid sequences set forth in SEQ ID NOS: 1 to 204 of the sequence listing, the polypeptides being plural kinds of single chain variable fragments (also referred to as ScFvs) each comprised of a heavy chain variable region, heavy chain constant region 1, and hinge region (VH-CH1-hinge) of an immunoglobulin, in which the heavy chain variable regions are different each other. | 2013-06-27 |
20130164291 | METHOD OF TREATING INFLAMMATORY BOWEL DISEASE - A method for treating or preventing an inflammatory bowel disease (IBD) in a subject, the method comprising administering to the subject a compound that inhibits granulocyte-macrophage colony stimulating factor (GM-CSF) signaling. | 2013-06-27 |
20130164292 | Human Anti-OPGL Neutralizing Antibodies As Selective OPGL Pathway Inhibitors - Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided. | 2013-06-27 |
20130164293 | BISPECIFIC BINDING AGENTS - The invention relates to bispecific anti-sclerostin/anti-DKK1 binding agents and combinations of anti-sclerostin and anti-DKK1 binding agents, and related methods of treatment. | 2013-06-27 |
20130164294 | SUBSTANCE SPECIFIC TO HUMAN PD-1 - The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy. | 2013-06-27 |
20130164295 | VEGF/DLL4 Binding Agents and Uses Thereof - The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer. | 2013-06-27 |
20130164296 | Excipients for Stabilising Viral Particles, Polypeptides or Biological Material - A sterile pharmaceutically acceptable aqueous solution, which solution is provided in a sealed container and comprises: a pharmaceutically acceptable aqueous solvent; viral particles or a physiologically active polypeptide; an excipient selected from a polyethyleneimine; a compound of formula (I) or a physiologically acceptable salt or ester thereof; or a compound of formula (II) or a physiologically acceptable salt or ester thereof; and optionally, one or more sugars. | 2013-06-27 |
20130164297 | MODULATION OF ACTIVITY OF NEUROTROPHINS - The present invention relates to methods for modulating the activity of one or more neurotrophins, such as neural growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3, and neurotrophin-4 (NT-4), in an animal and methods for treatment of a disease or disorder in an individual by modulation of neurotrophin activity. The modulation is carried out by interfering with binding between a neurotrophin and a receptor of the Vps10p-domain receptor family or modulating the expression of a receptor of the Vps10p-domain receptor family. Methods for screening for agents capable of modulating neurotrophin activity and agents selected using these screening methods are also disclosed, as are methods for determining the effect of an agent on one or more neurotrophins in cells. The present invention also pertains to methods for modulating the transport of one or more neurotrophins. | 2013-06-27 |
20130164298 | P. GINGIVALIS ANTIGENIC COMPOSITION - The present invention provides an antigenic composition, the composition comprising at least one recombinant protein. The recombinant protein comprises at least one epitope. The epitope is reactive with an antibody which is reactive with a polypeptide having the sequence set out in SEQ. ID. NO. 3 or SEQ. ID. NO. 5. The invention also provides methods and compositions for the production of the recombinant protein. Also provided are methods for the diagnosis, treatment and prevention of | 2013-06-27 |
20130164299 | LLT-1 ANTIBODIES WITH NEW FUNCTIONAL PROPERTIES - The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (LLT1), to polynucleotides encoding such antibodies and to cells that express such antibodies. Antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which LLT1- and CD161-expressing cells play a role in disease pathogenesis. | 2013-06-27 |
20130164300 | MONOCLONAL ANTIBODIES AND FRAGMENT THEREOF DIRECTED AGAINST THE HUMAN ANTI-MULLERIAN HORMONE TYPE II RECEPTOR (AMHR-II) - The present invention relates to monoclonal antibodies and fragment thereof directed against the human Anti-Müllerian Hormone type II receptor (AMHR-II) and their use for treating and diagnosing cancer diseases, such as ovarian cancers. | 2013-06-27 |
20130164301 | TREATMENT OF DISEASES LINKED TO PATHOLOGICAL KININ FORMATION - The present invention relates to the use of at least one antibody and/or one inhibitor for inhibiting factor XII and for preventing the formation and/or the stabilization of three dimensional thrombi. It also relates to a pharmaceutical formulation and the use of factor XII as an anti-thrombotic target. | 2013-06-27 |
20130164302 | Immuno-Modulating Compositions for the Treatment of Immune-Mediated Disorders - The present invention relates to immunomodulatory compositions comprising mammalian colostrum-derived immunoglobulin preparation and optionally further colostrums, milk or milk product component/s and any adjuvants for treating immune-related disorders. More specifically, the invention provides compositions comprising colostrum-derived anti-insulin immunoglobulin preparations for the treatment of Metabolic Syndrome. The invention further provides methods and uses of the immunomodulatory compositions for an active or passive immunization in a disease-antigen specific or non specific manner. | 2013-06-27 |
20130164303 | COMBINATION PREPARATION INCLUDING A CYTOKINE ANTAGONIST - The present invention relates to pharmaceutical compositions for a combination therapy with a cytokine antagonist and a corticosteroid. By means of the combination therapy diseases such as osteoarthritis, tendon injuries and/or degenerative spinal diseases can be treated. | 2013-06-27 |
20130164304 | ANTI-HEPCIDIN ANTIBODIES AND USES THEREOF - Monoclonal antibodies are provided that selectively bind human hepcidin-25 and are characterized as having high affinity for human hepcidin-25 and strong human mature hepcidin neutralizing properties. The antibodies of the invention are useful therapeutically for increasing serum iron levels, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a human and for the treatment and diagnosis of mature hepcidin-promoted disorders such as anemia, in a human subject. | 2013-06-27 |
20130164305 | METHOD FOR TARGET AND DRUG VALIDATION IN INFLAMMATORY AND/OR CARDIOVASCULAR DISEASES - A novel method for validating the utility of a drug in the treatment of inflammatory and cardiovascular diseases is described. | 2013-06-27 |
20130164306 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE AND INFLAMMATORY DISORDERS - Ligand-specific HVEM variants, compositions comprising such variants, and methods of treating inflammatory diseases comprising administering such variants, are provided. | 2013-06-27 |
20130164307 | USE OF CAMELID-DERIVED VARIABLE HEAVY CHAIN VARIABLE REGIONS (VHH) TARGETING HUMAN CD18 AND ICAM-1 AS A MICROBICIDE TO PREVENT HIV-1 TRANSMISSION - The invention provides methods, compositions, and kits featuring a camelid-derived antibody for use in preventing or inhibiting a viral infection. | 2013-06-27 |
20130164308 | STAPHYLOCOCCUS AUREUS SPECIFIC ANTIBODIES AND USES THEREOF - The present invention provides antagonizing antibodies that bind to | 2013-06-27 |
20130164309 | ANTIBODIES TO THE B12-TRANSCOBALAMIN RECEPTOR - The present invention provides anti-TCblR antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer, tumors and other proliferative diseases and disorders. | 2013-06-27 |
20130164310 | ANTI-DIABETIC COMPOUNDS - The present invention provides a composition of the formula: [FGF21-1 | 2013-06-27 |
20130164311 | COMPOSITION, PREPARATION, AND USE OF DENSE CHITOSAN MEMBRANE MATERIALS - A composition of exceptionally dense chitosan and a novel method for producing the dense chitosan structure have been described. The novel production method employs coincident compression and vacuum on a neutralized chitosan polymer that results in an exceptionally dense chitosan film or membrane material. The dense chitosan film or membrane composition possesses multiple physical and clinically appealing qualities for a variety of medical applications on or in animals, mammals, or humans. | 2013-06-27 |
20130164312 | METHODS AND MATERIALS FOR THE GENERATION OF REGULATORY T CELLS - Methods are disclosed for the generation of immunosuppressive regulatory T cells. The methods can include contacting a population of CD4+CD25− T cells with a T cell receptor (TCR)/CD3 activator, a TCR co-stimulator activator, and rapamycin. Kits for the generation of immunosuppressive regulatory T cells, methods of use, and cell populations are also disclosed. | 2013-06-27 |
20130164313 | DNA SEQUENCE, AND RECOMBINANT PREPARATION OF GROUP 4 MAJOR ALLERGENS FROM CEREALS - The present invention relates to the provision of DNA sequences of group 4 major allergens from cereals. The invention also encompasses fragments, new combinations of partial sequences and point mutants having a hypoallergenic action. The recombinant DNA molecules and the derived polypeptides, fragments, new combinations of partial sequences and variants can be utilised for the therapy of pollen-allergic diseases. The proteins prepared by recombinant methods can be employed for in vitro and in vivo diagnosis of pollen allergies. | 2013-06-27 |
20130164314 | CANCER PEPTIDE VACCINE - A composition for treating cancer, comprising 6 to 13 peptides derived from tumor antigens, wherein the composition is used in the manner that antibodies to the respective peptides in the peripheral blood of a patient are measured and peptides to which antibodies are positive are selected and administered to the patient, and a peptide selection method. | 2013-06-27 |
20130164315 | Vaccines - Screening Method - The present invention provides a screening method for identifying a peptide capable of inducing a T cell response comprising:
| 2013-06-27 |
20130164316 | GENETIC SIGNATURES IN HIV-1 SUBTYPE C ENVELOPE GLYCOPROTEINS - The present invention relates, in general, to HIV-1 and, in particular, to immunogens that elicit broadly neutralizing antibodies against HIV-1 subtype C envelope glycoproteins, and compositions comprising same. The invention further relates to methods of inducing the production of such antibodies in a subject. | 2013-06-27 |
20130164317 | ANTIMICROBIAL AGENT, BACTERIAL STRAIN, BIOSYNTHESIS, AND METHODS OF USE - Provided herein is a biologically pure culture of | 2013-06-27 |
20130164318 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES - The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce αGal epitopes or αGal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-αGal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal. | 2013-06-27 |
20130164319 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES - The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce αGal epitopes or αGal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-αGal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal. | 2013-06-27 |
20130164320 | NOVEL MICRO-ORGANISMS CONTROLLING PLANT PATHOGENS - The invention relates to control of pathogen caused diseases on leaves, fruits and ears in plants, such as apple scab ( | 2013-06-27 |
20130164321 | USE OF ANTRODIA CAMPHORATA FOR TREATING SKIN CONDITIONS - The present invention relates to the use of antrodia camphorata in the treatment of skin conditions, such as acne vulgaris, urticaria and eczema, allergic rhinitis, diabetes mellitus and its complications, cancer cachexia, hypercholesterolemia, gout in a subject in need of such treatment. The present invention is also directed to the use of antrodia camphorata in the prevention and treatment of oral cancer and arterial restenosis, in a subject in need of such prevention. The methods comprise the steps of: identifying a subject in need thereof, and administering to the subject a formulation comprising an effective amount of antrodia camphorata, whereby the symptoms in the subject are reduced or prevented. The composition can be a pharmaceutical composition or a nutraceutical composition. | 2013-06-27 |
20130164322 | CULTURED EXTREMOPHILIC ALGAE SPECIES NATIVE TO NEW MEXICO - Provided herein is an extremophile green alga designated as | 2013-06-27 |
20130164323 | COMPOSITIONS AND METHODS FOR TREATING SKIN - The present invention relates to skin care compositions comprising blends of | 2013-06-27 |
20130164324 | COMPOSITIONS OF MARINE BOTANICALS TO PROVIDE NUTRITION TO AGING AND ENVIRONMENTALLY DAMAGED SKIN - Disclosed is a topical skin composition comprising water, a first algae extract comprising | 2013-06-27 |
20130164325 | CERAMIDE-LIKE GLYCOLIPID-ASSOCIATED BACTERIAL VACCINES AND USES THEREOF - The invention is directed compositions and methods related to bacterial cells that are physically associated with ceramide-like glycolipids for use as antigen carriers for heterologous antigens. The invention further relates to methods of incorporating ceramide-like glycolipid to bacterial cell walls. The compositions and methods of the present invention are useful for the prevention and treatment of diseases. | 2013-06-27 |
20130164326 | CHIMERIC ADENOVIRAL VECTORS - The present invention provides chimeric adenoviral vectors and methods for using the vectors to elicit an immune response to an antigen of interest. | 2013-06-27 |
20130164327 | Adenovirus vaccine vectors - The invention relates to recombinant adenovirus displaying one or more heterologous epitope(s) on their fiber protein. These recombinant adenovirus are useful as vaccines for generating an immune response against said epitope(s) in individuals having a pre-existing anti-Ad immunity. | 2013-06-27 |
20130164328 | METHODS FOR ENHANCING IMMUNE RESPONSE - This disclosure demonstrates a novel therapy immunological approach using polyamine-based therapy (PBT) for relieving tumor-induced suppression of the patient's immune system. The demonstration of the pharmacological release from the naturally occurring polyamine-mediated immune suppression offers profound impact on the immunotherapy of cancer together with a variety of diseases caused by the disease-causing vector's ability to evade an immune reaction. This therapeutic approach is equally applicable to disease states whereby immune system suppression by polyamines has been demonstrated including; bacterial infections, parasitic infections including malaria and typanosomiasis, viral infections, peptic ulcers and gastric cancer due to | 2013-06-27 |
20130164329 | CELL-BASED METHODS AND REAGENTS - The present invention relates to compositions and methods for isolating cells devoid of unwanted viral contaminants, and to methods for preparing a virus stock substantially devoid of viral contaminants. Virus stocks, cells, and immunogenic reagents produced using such methods are also provided. | 2013-06-27 |
20130164330 | Methods and Compositions for Treatment of Hematologic Cancers - The present invention relates to oncolytic Picornaviruses and methods and compositions for treating subjects having hematologic cancers. These include methods and compositions for treatment of myeloma, using disclosed Picornavirus such as Coxsackievirus, in methods of direct or indirect administration to subjects and ex vivo purging of malignant cells within auto grafts prior to transplantation. | 2013-06-27 |
20130164331 | ORAL VACCINATION OF FISH WITH LIVE ATTENUATED EDWARDSIELLA ICTALURI VACCINES - The present invention is directed to a novel live attenuated isolate and sub-isolets thereof of a strain of the pathogen | 2013-06-27 |
20130164332 | LAWSONIA VACCINE AND METHODS OF USE THEREOF - The present invention provides improved vaccination methods for increased protection against ileitis. The methods provide for the vaccination of young animals, preferably piglets, between 10 and 26 days of age, vaccination of pregnant sows during the second or third stages of gestation, and a combination of these methods. Vaccination of the pregnant sows can occur using repeated and/or high doses of | 2013-06-27 |
20130164333 | IMMUNE STIMULATORY OLIGORIBONUCLEOTIDE ANALOGS CONTAINING MODIFIED OLIGOPHOSPHATE MOIETIES - Immunostimulatory oligoribonucleotides (ORN) featuring 5′-triphosphates and various 5′-triphosphate analogs are provided. Also provided are physiologically acceptable salts of the immunostimulatory ORN and pharmaceutical compositions containing the immunostimulatory ORN of the invention. ORN of the invention are useful as adjuvants and can be combined with an antigen to promote an antigen-specific immune response. ORN of the invention are also particularly useful for promoting a Th1-type immune response. Also provided are methods of use of the compounds and pharmaceutical compositions of the invention to enhance an immune response in a subject, as well to treat a number of conditions including cancer, infection, allergy, and asthma, and to vaccinate a subject against an antigen. | 2013-06-27 |
20130164334 | Dual Element Odor Control In Personal Care Products - An odor control layer for personal care products includes a first portion with a formulation of activated carbon and a second portion with a formulation of nanoparticle silver. The layer can be placed in a personal care product including diapers, training pants, absorbent underpants, adult incontinence products, or feminine hygiene products. The personal care product can include a liquid-permeable bodyside liner, a liquid-impermeable outer cover affixed to the bodyside liner, and an absorbent core disposed between the bodyside liner and the outer cover. | 2013-06-27 |
20130164335 | METHODS AND COMPOSITIONS FOR CELLULAR DRUG RELEASE - Methods and compositions for producing a cellular drug release are disclosed. The method comprises: a) providing a composition comprising a therapeutically effective amount of a pharmacological agent adsorbed onto mesoporous hydroxyapatite (HAP) with hydrophobic surfaces; b) exposing the composition to a cell; c) causing entry of the mesoporous HAP into the cell and degradation of the HAP in the lysosomes of the cell and desorption of the agent from the mesoporous HAP; d) causing release of the desorbed agent from the lysosomes into the cytoplasm of the cell; and e) causing release of the desorbed agent to outside the cell. The composition comprises a) mesoporous HAP with hydrophobic surfaces; and b) a therapeutically effective amount of a pharmacological agent, adsorbed onto the hydrophobic surfaces of the mesoporous. HAP. The composition is characterized in that it constantly releases the agent in vivo for a period of at least 4 weeks. | 2013-06-27 |
20130164336 | ANTIMICROBIAL AND ANTI-INFLAMMATORY ACTION PHARMACEUTICAL COMPOSITION FOR PARENTERAL ADMINISTRATION AND ITS PRODUCTION PROCESS - There is proposed herein a process for production of composite antimicrobial preparations for parenteral administration, featuring a higher therapeutic efficiency in case of grave infection and inflammatory diseases. The proposed compositions include an active agent being fosfomycin and finely dispersed nanostructured silica dioxide, with a weight ratio from 10:1 to 75:1 respectively. The mentioned production process includes mixing fosfomycin with finely dispersed nanostructured silica dioxide. Its main difference is that the mixture of aforementioned substances with the mentioned weight ratio is exposed to mechanical processing by blow impact and abrasive actions until a portion of the fine powder fraction with particles smaller than 5 micrometers, contained in the mixture, increases to at least 25%. The so obtained mixture is used for injection preparations. | 2013-06-27 |
20130164337 | ANTIMICROBIAL ACTION PHARMACEUTICAL COMPOSITION FOR PARENTERAL ADMINISTRATION AND ITS PRODUCTION PROCESS - There is proposed herein a process for production of composite antimicrobial preparations for parenteral administration, featuring a higher therapeutic efficiency in case of grave infection and inflammatory diseases. The proposed compositions include active agents being betalactam antibiotics and finely dispersed nanostructured silica dioxide with a weight ratio from 10:1 to 75:1 respectively. The silica dioxide particles are antibiotic molecules delivery agents into the phagocytes, which allows increasing the antimicrobial preparations concentration at inflammation areas and considerably decrease microorganisms antibiotic resistance. The mentioned production process includes mixing betalactam antibiotic with finely dispersed nanostructured silica dioxide. Its main difference is that the mentioned substances mixture with a weight ratio from 10:1 to 75:1 respectively is exposed to mechanical processing by impact and abrasive actions until a proportion of the fine powder fraction with particles smaller than 5 micrometers increases to at least 25%. The so obtained mixture is used for injection preparations. | 2013-06-27 |
20130164338 | TREATMENT OF CYSTIC FIBROSIS USING CALCIUM LACTATE, LEUCINE AND SODIUM CHLORIDE IN A RESPIRAPLE DRY POWDER - The invention relates to a methods for treating cystic fibrosis, comprising administering an effective amount of a calcium salt formulation to the respiratory tract of an individual with cystic fibrosis. The calcium salt formulation is can be a dry powder formulation. | 2013-06-27 |
20130164339 | PLATFORM FOR ENGINEERED IMPLANTABLE TISSUES AND ORGANS AND METHODS OF MAKING THE SAME - Disclosed are engineered tissues and organs comprising one or more muscle cell-containing layers, the engineered tissue or organ consisting essentially of cellular material, provided that the engineered tissue or organ is implantable in a vertebrate subject and not a vascular tube. | 2013-06-27 |
20130164340 | TROPOELASTINS AND USES THEREOF - The present invention relates to biocompatible polymeric scaffold materials, methods for making the materials and methods of using the materials. More particularly, the present invention relates to implants and grafts comprising polymeric scaffold materials of cross-linked human tropoelastin polypeptides and methods of making and using the same. In addition, the present invention provides alternatively spliced tropoelastin polynucleotides and polypeptides. | 2013-06-27 |
20130164341 | PREPARATION OF FORMULATIONS OF ANGIOTENSIN II AT1 RECEPTORS ANTAGONISTS FOR THE TREATMENT OF ARTERIAL HYPERTENSION, OTHER CARDIOVASCULAR ILLNESSES AND ITS COMPLICATIONS - Inclusion compounds consisting of certain Angiotensin II AT1 receptor antagonists and cyclodextrins are described. These inclusion compounds are useful in the treatment of hypertension. | 2013-06-27 |
20130164342 | FORMULATIONS FOR OSTEOPOROSIS - The present invention relates to effervescent formulations comprising genistein with an average particle size (d | 2013-06-27 |
20130164343 | COMPOSITIONS AND METHODS FOR ENHANCING TRANSPORT THROUGH MUCUS - The invention generally relates to compositions and methods for transporting substances across mucosal barriers. The invention also relates to methods of making and using such substances. | 2013-06-27 |
20130164344 | STABLE POWDER FORMULATION CONTAINING AN ANTICHOLINGERIC AGENT - The invention relates to a spray-dried powder formulation comprising particles that contain the following components i) to iii): i) anticholinergic agents, in particular at least one compound of formula 1, in which X | 2013-06-27 |
20130164345 | Co-Processing Method and Formulations for HIV Attachment Inhibitor Prodrug Compound and Excipients - A process for the production of a formulation of HIV attachment inhibitor piperazine tris salt prodrug compound involves dissolving the prodrug compound in a solvent to form a solution; adding a first quantity of a first anti-solvent to the solution; then dispersing a first quantity of HPMC in the solution; adding a second quantity of the first anti-solvent to the solution; dispersing a second quantity of HPMC in the solution; then adding a second anti-solvent to the solution so as to crystallize the compound with the HPMC and thereby form the formulation, wherein the second anti-solvent is a combination of acetone and isopropyl acetate (IPAC). The formulation is then washed, and dried. | 2013-06-27 |
20130164346 | METHOD FOR PREPARING BIOMEDICAL METAL ALLOY MATERIAL WITH MULTI-DRUG DELIVERY SYSTEM - The present invention provides a method for preparing a biomedical metal alloy material with a multi-drug delivery system. A biomedical metal alloy material with a multi-drug delivery system according to the present invention is prepared by incorporating a therapeutic agent into a biodegradable material to prepare particles containing the therapeutic agent, treating the surface of the particles containing the therapeutic agent to have a charge opposite to the surface charge of a metal alloy material, and inducing an electrostatic interaction between the surface charges of the particles containing the therapeutic agent and the metal alloy material to immobilize the surface-treated particles containing the therapeutic agent on the surface of the metal alloy material. | 2013-06-27 |
20130164347 | MULTILAYER POLYMERIC DRUG DELIVERY SYSTEM - The invention relates to a customizable, solvent-free sustained release medical device for wound closure, wound healing, and the sustained release of an active. The device of the invention is composed of at least a polymeric carrier layer and optionally an oxidized regenerated cellulose layer(s). Polymeric barrier layers can be added to modify the release profile (burst, time of release, etc.) of the selected bioactive agent(s). | 2013-06-27 |
20130164348 | MEDICAL DEVICES FOR DELIVERY OF THERAPEUTIC AGENTS - The present invention is generally directed to medical devices, and more specifically to medical devices that are at least partially insertable or implantable into the body of a patient. The medical devices generally comprise (a) a therapeutic agent, more typically, a high-molecular-weight therapeutic agent, and (b) at least one polymeric layer, which typically acts to control the release of the therapeutic agent from the medical device. Also disclosed herein are methods of making such medical devices. | 2013-06-27 |
20130164349 | Pulmonary Delivery for Levodopa - In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung. | 2013-06-27 |
20130164350 | SUSTAINED RELEASE FORMULATION OF NALBUPHINE - Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided. | 2013-06-27 |
20130164351 | METHODS OF TREATING BACTERIAL INFECTIONS THROUGH PULMONARY DELIVERY OF FUSIDIC ACID - Methods for the treatment of bacterial infections in the respiratory system of a subject, such as the lungs of a subject, using fusidic acid alone or in combination with a second bacterial agent such as tobramycin, amikacin, fosfomycin or levofloxacin are described. | 2013-06-27 |
20130164352 | ANTIPERSPIRANT COMPOSITIONS AND PRODUCTS EFFECTIVE TO FACILITATE PREVENTING, REMOVING OR MINIMIZING FABRIC STAINS AND METHODS FOR MAKING THE SAME - Antiperspirant compositions, products, and methods for making antiperspirant compositions and products are provided herein. In an exemplary embodiment, an antiperspirant composition comprises an active antiperspirant compound and an active cleaning agent that is effective to facilitate preventing, removing or minimizing fabric stains. | 2013-06-27 |
20130164353 | FUSION PEPTIDES COMPRISING MULTI-FUNCTIONAL PEPTIDIC SOLUBILITY TAGS FOR EFFICIENT PRODUCTION, PROCESSING AND SURFACE APPLICATIONS - Compositions and methods using fusion peptides comprising multi-functional solubility tags are provided. The multi-functional peptidic solubility tags facilitates more efficient fusion peptide production, easier downstream processing of the fusion peptide, and may be used to provide functional surface properties when coupled to a target material. | 2013-06-27 |
20130164354 | METHOD FOR THE EXTEMPORANEOUS PREPARATION OF COSMETIC COMPOSITIONS HAVING THE TEXTURE OF A CREAM AND COMPOSITIONS FOR CARRYING OUT SAID METHOD - Disclosed is a method for the preparation of cosmetic compositions having the texture of a cream. Said preparation is made at the time when the composition is used and includes bringing into contact with each other (A) a liquid phase, (B) a powder containing a gelling agent for the liquid phase (A), and (C) an active cosmetic ingredient, whereby the elements are brought into contact by adding phase (A) to phase (B), subjecting a solid powder containing phase (B) and phase (A) in an immobilized form to mechanical stress to release phase (A). Further disclosed are compositions comprising phase (B) and phase (A) in an immobilized form which are transformed into a cream when applied to the skin). | 2013-06-27 |
20130164355 | CORE SHELL MICROCAPSULES AND LIQUID CONSUMER PRODUCT - The present invention relates to core shell microcapsules for use in liquid consumer products, wherein: the microcapsule shell is made of starting materials such that 50%-100% by weight of said materials have a density equal to or less than 1.05 g/cm | 2013-06-27 |
20130164356 | EFFECT PIGMENTS - The present invention relates to effect pigments which are based on flake-form substrates having a circular form factor of 1.2-2 and are coated with at least one high-refractive-index layer, and to the use thereof, inter alia in paints, coatings, printing inks, plastics and in cosmetic formulations. | 2013-06-27 |
20130164357 | ZINC OXIDE POWDER BLENDS, THEIR PRODUCTION AND USE - This disclosure provides sunscreen products that contain metal oxide powders having discrete size distributions. Metal oxide powders include, for example, zinc oxide and titanium dioxide. Sunscreen products made in accordance with the principles of this disclosure contain metal oxide powders having primary particle sizes of about 10-30 ran and about 50-200 nm. | 2013-06-27 |
20130164358 | ORAL COMPOSITIONS COMPRISING A ZINC COMPOUND AND AN ANTI-MICROBIAL AGENT - Oral compositions and methods of use thereof are provided herein. The oral compositions comprise a first component comprising at least one Eh-raising compound and a pharmaceutically acceptable carrier, and a second component comprising at least one zinc compound, an anti-microbial agent and a pharmaceutically acceptable carrier. | 2013-06-27 |
20130164359 | COMPOSITE PARTICLE ACTIVE AND METHOD FOR MAKING THE SAME - Composite particle actives suitable for use in oral care compositions are described. The composite particle actives have a core and a coating whereby the coating interacts with phosphate ions to produce calcium and phosphate reaction products that are suitable to adhere to tooth enamel and/or dentin in order to improve characteristics of teeth. | 2013-06-27 |
20130164360 | Hemostatic Materials and Devices with Galvanic Particulates - The present invention is directed to a hemostatic material comprising a scaffold and a galvanic particulate. The galvanic particulate comprises particles made of at least two dissimilar metals. The scaffold is preferably a biocompatible polysaccharide-based hemostatic, such as a chitosan or cellulosic based hemostatic like ORC. | 2013-06-27 |
20130164361 | ENHANCED FORMULATIONS, COMPOSITIONS AND METHODS FOR PEST CONTROL - Formulations of pesticides are disclosed, specifically pesticidal blends of essential oils and other ingredients, that have been found to enhance the activity of the active pesticidal ingredients. The formulations may be, for example, emulsions or dust formulations. For example, a composition for controlling a target pest is disclosed that comprises at least one active agent and a formulation agent, wherein: the active agent is capable of interacting with a receptor in the target pest; the active agent has a first activity against the target pest when applied without the formulation agent and the composition has as a second activity against the target pest; and the second activity is greater than the first activity. | 2013-06-27 |
20130164362 | PARTICULATE WOOD PRESERVATIVE AND METHOD FOR PRODUCING SAME - A wood preservative includes injectable particles comprising one or more sparingly soluble copper salts. The copper-based particles are sufficiently insoluble so as to not be easily removed by leaching but are sufficiently soluble to exhibit toxicity to primary organisms primarily responsible for the decay of the wood. Exemplary particles contain for example copper hydroxide, basic copper carbonate, copper carbonate, basic copper sulfates including particularly tribasic copper sulfate, basic copper nitrates, copper oxychlorides, copper borates, basic copper borates, and mixtures thereof. The particles typically have a size distribution in which at least 50% of particles have a diameter smaller than 0.25 μm, 0.2 μm, or 0.15 μm. At least about 20% and even more than 75% of the weight of the particles may be composed of the substantially crystalline copper salt. Wood or a wood product may be impregnated with copper-based particles of the invention. | 2013-06-27 |
20130164363 | ANTIMICROBIAL FLUSH SOLUTIONS - The present invention provides antimicrobial solutions that comprise at least one alcohol, at least one antimicrobial agent and at least one chelator and/or anticoagulant. Also provided are methods for rapidly reducing a microbe or a virus from surfaces including surfaces of indwelling medical devices and organic surfaces such as skin and sutures, and inorganic surfaces such as hospital equipment, pipelines etc. | 2013-06-27 |
20130164364 | LIPOSOME TARGETING COMPOUNDS AND RELATED USES - The present invention provides liposome targeting compounds for targeting cells expressing sialic acid binding Ig-like lectin (Siglec). The liposome compounds typically comprise a binding moiety that is a glycan ligand of the Siglec on the target cell. The liposome compounds also incorporate or encapsulate a biological agent (e.g., an antigen or a therapeutic agent) that can be delivered to the target cell to modulate or kill the target cell. The invention also provides methods of using the liposome targeting compounds for targeted delivery of antigen and for modulating immune cells or immune responses. | 2013-06-27 |
20130164365 | FORMULATIONS FOR TREATMENT WITH GLUCOSINOLATES - The application relates to topical formulations comprising a phase II enzyme inducer precursor and an activating agent. Methods for producing and using the topical formulations are also provided. | 2013-06-27 |
20130164366 | Method and medicament for inhibiting the expression of a given gene - The invention relates to an isolated RNA that mediates RNA interference of an mRNA to which it corresponds and a method of mediating RNA interference of mRNA of a gene in a cell or organism using the isolated RNA. | 2013-06-27 |
20130164367 | TREATMENT OF NEURODEGENERATIVE DISEASE WITH CREB-BINDING PROTEIN - The present invention relates to improving cognition and treating of neurodegenerative disease using CREB-binding protein. The protein may be delivered to the brain by an expression vector, in particular a lentiviral vector. | 2013-06-27 |
20130164368 | HEPAROSAN POLYMERS AND METHODS OF MAKING AND USING SAME FOR THE ENHANCEMENT OF THERAPEUTICS - Compositions, methods, and systems are disclosed for the development and use of heparosan, a natural polymer related to heparin, as a new therapeutic modifying agent or vehicle which can modulate drug cargo pharmacokinetics and behavior within a mammalian patient. | 2013-06-27 |
20130164369 | TELODENDRIMER NANODISCS WITHOUT APOLIPOPROTEIN - The present invention provides a nanodisc without a membrane scaffold protein. The nanodisc includes a telodendrimer and a lipid; the nanodisc does not include a membrane scaffold protein. The telodendrimer has the general formula PEG-L-D-(R) | 2013-06-27 |
20130164370 | NOVEL FORMULATION OF PEGYLATED-LIPOSOME ENCAPSULATED GLYCOPEPTIDE ANTIBIOTICS - This invention is directed to a novel method of treating an individual suffering from a bacterial infection, such as bacterial infections of various tissues or organs of an individual. In general, the method of treatment involves administering to an individual a pharmaceutical formulation that comprises a liposome-encapsulated antimicrobial agent, wherein polyethylene glycol (PEG) molecules are covalently attached to the surface of the liposomes. | 2013-06-27 |
20130164371 | THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE - Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract. | 2013-06-27 |
20130164372 | THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE - Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract. | 2013-06-27 |
20130164373 | THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE - Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract. | 2013-06-27 |
20130164374 | REDUCTION IN BACTERIAL COLONIZATION BY ADMINISTERING BACTERIOPHAGE COMPOSITIONS - The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage. | 2013-06-27 |
20130164375 | METHODS OF TREATING HYPERTRIGLYCERIDEMIA - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof | 2013-06-27 |
20130164376 | FORMULATIONS OF (+)-2-[1-(3-ETHOXY-4-METHOXY-PHENYL)-2-METHANESULFONYL-ETHYL]-4-ACETYLAMI- NOISOINDOLINE-1,3-DIONE - Pharmaceutical compositions and single unit dosage forms of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate thereof, are provided herein. Also provided are methods of treating, managing, or preventing various diseases or disorders. | 2013-06-27 |